Clinilabs Drug Development Corporation is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system drug development.
Ulysses Neuroscience Ltd is a patient-centric private R&D organization working together with pharmaceutical companies in order to accelerate drug discovery in neuropsychiatric (major depression, anorexia nervosa and schizophrenia) and neurodevelopmental (Fragile X Syndrome and CDKL5 Deficiency Disorders) diseases by using translation clinical and pre-clinical research. Our translational research investigates neurophysiological and molecular mechanisms leading to the synaptic pathology, microtubule dynamics dysregulation and neuroinflammatory events.
PinneyAssociates’ Rx team supports clients in the development of CNS-active drugs, from traditional pharmaceuticals to psychedelics and cannabinoids. Whether you are seeking high level strategic advice or hands-on team support, Pinney has the clinical development, abuse liability, and regulatory expertise to help you both map and navigate the path forward. Services include clinical and regulatory strategy, 8-factor analysis and abuse potential assessment, abuse-deterrent formulation evaluation, and REMS development and management
PsychoGenics is revolutionizing neuropsychiatric drug discovery through our AI-driven, high-throughput, phenotypic platform called SmartCube. We have an extensive pipeline of partnered and internal programs, the most advanced of which is in Phase III, developed in collaboration with Sunovion. SEP-856 was recently awarded Breakthrough Therapy Designation for Schizophrenia due to an absence of side effects, a broader therapeutic effect, and non-Dopamine D2 mechanism of action
Inscopix is a neurotechology company developing preclinical solutions for real-time brain mapping to drive new treatments designed to improve the health and well-being of people suffering from debilitating brain disorders. Inscopix’s flagship miniscope systems have been deployed in over 500 research institutions worldwide resulting in over 170 top-tier scientific publications.
As many brain orders are understood to be a dysregulation of neural circuits, biopharma is harnessing the Inscopix neural circuit platform for an end-to-end, data-driven method to de-risk neurotherapeutic preclinical drug development. Key areas of focus range from circuit-based pharmacodynamics and dose-finding to efficacy and disease areas span from Alzheimer’s, Parkinson’s, chronic pain, addiction to psychiatric disorders.
Based in the heart of Silicon Valley, our team brings together deep domain expertise in neuroscience, engineering, and data science. We are committed to partnering with you on the next generation of neurotherapeutics to improve brain health.
Apex Innovative Sciences
Apex Innovative Sciences is a global provider of clinical development and site services. Apex represents the consolidation of core businesses including Hassman Research Institute, CNS Network and Clinical Trial Centers Alliance. The expanded team collaborates to provide quality, efficiency, and value in the development of innovative medicines. Apex helps sponsors achieve go/no-go decisions, reduce development costs, and deliver high quality results. Apex is committed to providing scientific, technological, and organizational expertise in phase I - IV clinical trials, including neurology, psychiatry, addiction, Asian bridging, pain, healthy subjects and general medicine. The company prides itself on delivering the highest scientific and clinical quality for its client partners and participants.
For more information about Apex, please visit: www.ApexSci.com